Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
Read the full articleYou might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer
theguardian.com·1mo ago
Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials
The pancreatic-cancer drug could be the first of an entirely new class of treatments
economist.com·13d agoFirst RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
Jun 1, 2026 - By Erin Post NEW — Additional Data on Daraxonrasib Released: “Significant Advances” for Pancreatic Cancer Treatment Daraxonras
A New Hope for Advanced Pancreatic Cancer: Daraxonrasib Shows Remarkable Results
Pancreatic cancer is still one of the toughest cancers to treat. Once the disease starts growing again after the first round of treatment, t
PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial at ASCO
Jun 1, 2026 - By Julie Vasquez The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress again
Our response to the daraxonrasib clinical study and KRAS inhibitors
Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors. The post Our response to the daraxonrasib
Comments
Sign in to join the conversation.
No comments yet. Be the first.